G1 Therapeutics, Inc. Stock

Equities

GTHX

US3621LQ1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
3.3 USD -0.30% Intraday chart for G1 Therapeutics, Inc. -19.32% +8.20%
Sales 2024 * 70.95M Sales 2025 * 95.42M Capitalization 173M
Net income 2024 * -31M Net income 2025 * -21M EV / Sales 2024 * 2.43 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.81 x
P/E ratio 2024 *
-6.06 x
P/E ratio 2025 *
-11 x
Employees 100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.42%
More Fundamentals * Assessed data
Dynamic Chart
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results CI
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting CI
Sector Update: Health Care Stocks Lower Premarket Wednesday MT
G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell MT
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses CI
Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M MT
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib CI
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating MT
Transcript : G1 Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M MT
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024 CI
More news
1 day-0.30%
1 week-19.32%
1 month-12.47%
3 months-0.60%
6 months+75.53%
Current year+8.20%
More quotes
1 week
3.07
Extreme 3.07
4.21
1 month
3.07
Extreme 3.07
6.14
Current year
2.01
Extreme 2.01
6.14
1 year
1.08
Extreme 1.08
6.14
3 years
1.08
Extreme 1.08
24.12
5 years
1.08
Extreme 1.08
41.80
10 years
1.08
Extreme 1.08
69.57
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20-03-11
Director of Finance/CFO - 17-12-31
Chief Tech/Sci/R&D Officer 65 14-06-30
Members of the board TitleAgeSince
Director/Board Member 65 15-08-31
Director/Board Member 64 18-06-06
Founder 57 08-05-18
More insiders
Date Price Change Volume
24-05-31 3.3 -0.30% 677,169
24-05-30 3.31 -0.90% 847,146
24-05-29 3.34 -1.76% 1,020,711
24-05-28 3.4 -16.87% 2,794,137
24-05-24 4.09 -3.08% 711,392

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.3 USD
Average target price
8.5 USD
Spread / Average Target
+157.58%
Consensus